Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bio-Techne (TECH) Cash & Equivalents (2016 - 2025)

Historic Cash & Equivalents for Bio-Techne (TECH) over the last 17 years, with Q4 2025 value amounting to $172.9 million.

  • Bio-Techne's Cash & Equivalents fell 263.03% to $172.9 million in Q4 2025 from the same period last year, while for Dec 2025 it was $172.9 million, marking a year-over-year decrease of 263.03%. This contributed to the annual value of $162.2 million for FY2025, which is 684.82% up from last year.
  • As of Q4 2025, Bio-Techne's Cash & Equivalents stood at $172.9 million, which was down 263.03% from $145.0 million recorded in Q3 2025.
  • Bio-Techne's 5-year Cash & Equivalents high stood at $211.8 million for Q4 2021, and its period low was $127.3 million during Q1 2023.
  • For the 5-year period, Bio-Techne's Cash & Equivalents averaged around $166.0 million, with its median value being $165.0 million (2022).
  • In the last 5 years, Bio-Techne's Cash & Equivalents soared by 3643.76% in 2024 and then tumbled by 2270.34% in 2025.
  • Quarter analysis of 5 years shows Bio-Techne's Cash & Equivalents stood at $211.8 million in 2021, then decreased by 22.26% to $164.7 million in 2022, then fell by 20.98% to $130.1 million in 2023, then soared by 36.44% to $177.5 million in 2024, then decreased by 2.63% to $172.9 million in 2025.
  • Its Cash & Equivalents was $172.9 million in Q4 2025, compared to $145.0 million in Q3 2025 and $162.2 million in Q2 2025.